Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Photocure ASA is a Norwegian specialty pharmaceutical company specializing in photodynamic technology for cancer diagnostics and treatment. Headquartered in Oslo and founded in 1993, it focuses primarily on bladder cancer solutions, positioning itself as 'The Bladder Cancer Company.' Its flagship product, Hexvix/Cysview, enables the detection of bladder cancer by making cancer cells glow bright pink during cystoscopy procedures, improving diagnosis accuracy and patient outcomes. This product is commercialized through direct sales in key markets like North America and Europe, and via partners in regions including China, Australia, New Zealand, Chile, and Israel. Photocure operates in two segments: Commercial Franchise, generating revenue from Hexvix/Cysview, and Development Portfolio, which includes Cevira for treating HPV-induced cervical precancerous lesions under license with Asieris MediTech. The company also collaborates with Richard Wolf GmbH on advanced cystoscopy systems. With around 100 employees, Photocure sells to wholesalers, pharmacies, and hospitals worldwide, emphasizing innovation in the underserved bladder cancer market.